Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smarter glucose monitor stop dangerous lows? small study tests predictive alerts

NCT ID NCT07614139

Symptom relief Sponsor: University Hospital Padova Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tested whether a continuous glucose monitor with predictive alerts (Dexcom G7) can reduce low blood sugar better than a standard alert monitor (Dexcom ONE+) in 11 adults with glycogen storage disease or congenital hyperinsulinism. Participants wore each device for 30 days, checked blood sugar, and filled out questionnaires. The goal was to see if early warnings help prevent hypoglycemia and improve quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Continuous glucose monitor (Dexcom G7 and Dexcom ONE+)
What this could lead to
If predictive alerts work better, this could help people with metabolic disorders avoid dangerous low blood sugar episodes and improve daily life.
What could go wrong
This was a very small study (11 people) and only looked at short-term use. Results may not apply to everyone, and the device may not be accurate for all users.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

11 people

The number who actually took part.

Started

Jan 2025

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Genetic or biochemical diagnosis of Glycogen Storage Disease (GSD) or Congenital Hyperinsulinism (CH) * At least one clinical and biochemical follow-up at the hospital outpatient service within the last one or two years * Ability to sign informed consent and comply with study procedures Exclusion Criteria: * Inability to sign informed consent or comply with study procedures

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Congenital hyperinsulinism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Congenital Hyperinsulinism disorder of glycogen metabolism familial hyperinsulinism hypoglycemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Congenital hyperinsulinism (CHI) Glycogen storage disease Hypoglycemia

Contacts and locations

Locations

  • University Hospital of Padova

    Padova, Padova, 35128, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.